Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

PRINCETON, N.J., Feb. 7, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended December 31, 2010.

Financial ResultsRevenues were $0.2 million during the quarter ended December 31, 2010 compared to $0.3 million for the quarter ended December 31, 2009 and include amortization of up-front and subsequent collaborative and license payments received from Roche.

Net cash used in operating activities during the three months ended December 31, 2010 was $24.0 million. Pharmasset held $102.7 million in cash and cash equivalents as of December 31, 2010. On January 26, 2011, we completed a common stock offering raising an additional $123.4 million.

Total operating expenses for the quarter ended December 31, 2010 were $23.8 million as compared to $13.4 million for the same period in 2009. The increase in operating expenses for the quarter ended December 31, 2010 was primarily the result of preclinical and clinical trial costs for PSI-7977 and PSI-938 of which $5.9 million was related to API manufacturing (and related drug supply) costs and pegylated interferon and ribavirin costs for the studies of PSI-7977 and PSI-938.

Pharmasset reported a net loss of $23.5 million, or $0.69 per share, for the quarter ended December 31, 2010, as compared to a net loss of $13.9 million, or $0.49 per share, for the quarter ended December 31, 2009.

Recent Operational Highlights:-- Presented final Phase 2a results with PSI-7977 at the American Association for the Study of Liver Diseases (AASLD) in October 2010

-- Initiated Part 2 of a Phase 1 study that includes combinations of PSI-7977 and PSI-938

-- Roche reported 12 week interim results f
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... N.J. , July 30, 2015  Unichem Pharmaceuticals ... recalling one lot of Hydrochlorothiazide tablets 25 mg 1000-count ... initiated as a precautionary measure due to the identification ... the product. The risk associated with ... tablet is the increased probability of experiencing Clopidogrel,s side ...
(Date:7/30/2015)... -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today ... the second quarter ending June 30, 2015. ... organization.  We are excited to be near the completion ... conducted with topline results expected in the fourth quarter," ... Therapeutics, Inc. "Translarna is now commercially available in 12 ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10
... July 9 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... improvement in rheumatoid arthritis (RA) patients in the recently completed ... up to 6 months. The groups treated with 100 ... qd (once a day) reported higher ACR 20, ACR 50, ...
... , THOUSAND OAKS, Calif., July 7 Amgen (Nasdaq: ... Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic ... patients with advanced breast cancer met its primary and ... Superiority was demonstrated for both delaying the time ...
Cached Medicine Technology:Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 2Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 3Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 4Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 5Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 6Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 2Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 3Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 4Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 5Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 6Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 7Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases 8
(Date:8/1/2015)... ... August 01, 2015 , ... Brig and Lita Hart, icons of ... unification of their Healthy Home mission with the HOPE Movement of EvolvHealth. In what ... of both companies have agreed to join their missions of purpose together to change ...
(Date:8/1/2015)... ... August 01, 2015 , ... On Tuesday, July 28th, Symantec released a security ... have been behind the attack on Anthem Inc. which resulted in one of the ... hole attacks and spear phishing campaigns. , For Joe Caruso, founder and ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:8/1/2015)... ... ... Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) – began ... and heading north. Since that day, Phil has hiked over 1400 miles in nine states. ... family. He visited CCAR and left an inspirational message to his staff: “You can ...
(Date:7/31/2015)... ... 31, 2015 , ... Ticket Down is a reputable source of authentic tickets for the ... Fans of every genre of music will have an act they are excited to ... the festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, The Who, ...
Breaking Medicine News(10 mins):Health News:Looking for HOPE? Healthy Home Has Evolv’d 2Health News:Looking for HOPE? Healthy Home Has Evolv’d 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:March4thforWellBeing Foundation Kickoff 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3
... health committee is all set to tighten the screws ... days of public hearing starting on Jan 23, is ... will make submissions before the committee. ,Under ... the sponsorship of sports and other popular events by ...
... way that primary care is organized, delivered, financed, and ... were released today by the American College of Physicians ... the Nation's Health Care. ,The U.S. health ... medicine, the ACP reported in its January 2006 State ...
... viral culture system, which makes way for a better ... replication of virus// (isolated from patient) in non-transformed hepatocytes. ... in transformed cell lines. ,The study report ... transfected and serum-infected cultured human fetal hepatocytes,’ appears in ...
... been accomplished by people who have kept on trying when there ... ,A groundbreaking venture has been ... cancer-treatment, are mass-produced in the egg white of a certain breed ... is one of the leading causes of death in the world. ...
... known as microchimerism has been known for some years, that ... pregnancy, and that these may live on for many// years, ... still unclear as to whether the presence of such cells ... team has looked for maternal cells in children with type ...
... findings that point to yet another benefit of statins; improving ... prescribed for heart patients. They work by lowering the levels ... in arteries. ,The drugs have also been shown ... of heart disease from having a heart attack or stroke. ...
Cached Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:A Breakthrough in the Study of Hepatitis C 2Health News:'Hen Factories' To Synthesize Cancer Drugs 2Health News:Stem Cells Passed From Mother to Child Live On and Make Insulin 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
Soft Non-Latex, Adjustable Flange Nasopharyngeal Airway. Pediatric sizes available. Non-Latex Mediprene material with soft elastic finish. Adjustable flange for a better fit and increased patient com...
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Flexible vinyl with a rigid bite block. Guedel-style with three internal channels. Individually packaged, 48 per case. Latex Free....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: